With the encouraging results for The Pfizer-BioNTech, Moderna, and Oxford/AstraZeneca COVID-19 vaccines, there has been much discussion on the temperature-controlled logistics challenges associated with distributing the vaccine once approval is granted. Vaccines are typically stored at between -2oC and +8oC, while the Pfizer-BioNTech vaccine needs to be kept at around -70oC during transportation.
The extremely low temperature required during transportation makes dry ice an ideal solution. Pfizer plans to ship up to 1.3 billion doses next year, which will be stored with dry ice in isothermic boxes that will hold up to 975 vials (4,875 doses).
Polar Ice, as an approved supplier to Ireland’s major pharma and life sciences companies, has already catered for the dry ice used to ship and freeze Covid-19 testing kits sent to Germany for analysis, as Irish testing facilities reached capacity.
We are well placed to meet periods of high demand. Our established manufacturing facility can meet Ireland’s dry ice needs twice over. There is a further €1m development underway on an adjoining site and on-going investment in our award-winning distribution team. We are a niche company; this is what we do day in day out, and we are ready, when required, to rise to this challenge without disruption to our existing customers.
#dryice #temperaturecontrol #COVID19 #vaccine
